• Bayer, Sanofi in executive swap as French drugmaker refocuses two global business units firstwordpharma
    September 14, 2018
    Bayer announced Thursday that Stefan Oelrich, who currently heads Sanofi's global diabetes and cardiovascular business, will join the company to lead its pharmaceuticals division, replacing Dieter Weinand.
  • With drugs pipeline in focus, Bayer considers job cuts financialexpress
    September 05, 2018
    The savings that Bayer – the inventor of aspirin and maker of Yasmin birth control pills – could make as part of the overhaul would give it financial wiggle room as it competes with larger rivals to buy the right to promising treatments from biotech firms
  • Bayer’s new haemophilia A drug obtains FDA approval pharmaceutical-technology
    September 03, 2018
    Bayer has received approval from the US Food and Drug Administration (FDA) for its new haemophilia A drug Jivi (BAY94-9027) as routine prophylactic therapy in previously treated adults and adolescents aged 12 years and above.
  • Bayer Receives FDA Approval for Jivi americanpharmaceuticalreview
    August 31, 2018
    Bayer announced the U.S. Food and Drug Administration (FDA) has approved Jivi (BAY94-9027, antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of
  • Bayer accelerates six new startups worldpharmanews
    August 31, 2018
    Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year.
  • Roundup cancer verdict sends Bayer shares sliding Reuters
    August 16, 2018
    Bayer's newly acquired Monsanto was ordered to pay $289 million in damages in the first of possibly thousands of U.S. lawsuits over alleged links between a weedkiller and cancer.
  • Janssen, Bayer to close South Korean plants due to limited demand fiercepharma
    August 06, 2018
    Another drugmaker will close up manufacturing in South Korea. Janssen Korea will shutter its Hyangnam plant in Hwaseong, South Korea, by 2021, laying off an undetermined number of workers.
  • LEO Pharma to acquire Bayer’s prescription dermatology portfolio pharmaceutical-technology
    August 03, 2018
    Denmark-based LEO Pharma has signed a definitive agreement to acquire Bayer’s global prescription dermatology unit in a bid to expand its therapeutic areas and bolster a global footprint.
  • Bayer to sell prescription dermatology unit and transfer 450 employees to Leo Pharma fiercepharma
    August 01, 2018
    With an ambition to expand its position as a leading dermatology company, Leo Pharma has agreed to acquire Bayer’s prescription dermatology business, which delivered €280 million ($328 million) in 2017 sales.
  • Bayer dismisses Essure concerns as safety, legal claims mount fiercebiotech
    July 31, 2018
    Bayer pushed back on the clinical safety of its Essure contraceptive implant—a week after the company said it would pull the device from the market at the end of the year due to poor sales—as public and legal pressure continue to mount regarding reports o
PharmaSources Customer Service